Clinical Review

An Analysis of the Clinical Trial Landscape for Cutaneous Melanoma

Cutis. 2015 September;96(3):186-190

References

1. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252-271.

2. American Cancer Society. Cancer Facts and Figures 2015. American Cancer Society Web site. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed August 26, 2015.

3. Cheng MY, Moreau JF, McGuire ST, et al. Melanoma depth in patients with an established dermatologist. J Am Acad Dermatol. 2014;70:841-846.

4. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14:e60-e69.

5. Kim SH, Tanner A, Friedman DB, et al. Barriers to clinical trial participation: a comparison of rural and urban communities in South Carolina. J Community Health. 2014;39:562-571.

6. Gregg JR, Horn L, Davidson MA, et al. Patient enrollment onto clinical trials: the role of physician knowledge. J Cancer Educ. 2014;29:74-79.

7. Galsky MD, Hendricks R, Svatek R, et al. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the
Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013;119:1994-1998.

8. Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database—update and key issues. N Engl J Med. 2011;364:852-860.

9. Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist. 2013;18:717-725.

10. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323-332.

11. Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther. 2014;8:775-787.

12. Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161-169.

13. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.

14. Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.

15. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39.

16. Espinosa E, Berrocal A, López Martin JA, et al. Advances in cutaneous melanoma. Clin Transl Oncol. 2012;14:325-332.

17. Chapman PB. Treating metastatic melanoma in 2014: what just happened and what is next? Am Soc Clin Oncol Educ Book. 2014:16-19.

18. Eggermont A, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-530.

19. Curry JL, Tetzlaff MT, Nicholson K, et al. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014; 36:557-561.

20. Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134:1351-1358.

21. Ross MI, Andtbacka RI, Puzanov I, et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): results from a phase III trial in patients with stage IIIb-IV melanoma. Paper presented at: ASCO Annual Meeting; June 2, 2014; Boston, MA.

22. Postow MA, Chesney J, Pavlick AC, et al. Novolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.

23. Gorantla VC, Kirkwood JM. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014;28:415-435.

24. Coit DG, Olszanski AJ. Progress in the management of melanoma in 2013. J Natl Compr Canc Netw. 2013; 11(5 suppl):645-648.

25. Watson M, Johnson CJ, Chen VW, et al. Melanoma surveillance in the United States: overview of methods. J Am Acad Dermatol. 2011;65(5, suppl 1):S6-S16.

Our study also highlights the dynamic nature of the field. For example, novel vaccine therapies have demonstrated promise in the metastatic/  unresectable tumor setting, with some herpes simplex virus–based vaccines generating durable antitumor immune responses in patients with melanoma.²¹ Combination therapy with CTLA-4 and PD-1 inhibitors has demonstrated improved objective response rates and progression-free survival over monotherapy.²² As the status of actively recruiting trials changes on a regular basis, we encourage physicians to access ClinicalTrials.gov to find details and contact information for actively recruiting trials and results on completed trials.

Early detection and management, however, still remain our primary option for cure, and the role of community dermatologists cannot be overstated.²³ Patients with stage I and stage II disease have excellent long-term survival rates, yet only 6% of all clinical trials in cutaneous melanoma have focused on patient education, disease prevention, early detection, and local management. With an increasing incidence of melanoma among an aging population, the disease burden remains of substantial concern.²⁴ Optimizing disease prevention, appropriate screening, and early detection are critical roles for dermatologists.

Finally, our data offer some insight into accrual barriers often faced by clinical trials. Actively enrolling clinical trials cluster within major metropolitan areas, presumably with large academic medical centers; however, areas in the southwestern United States and Florida, for example, have some of the highest burden of disease, likely secondary to sun exposure and aging populations.²⁵ Integration of community dermatologists and oncologists may decrease both actual and patient-perceived barriers to care, which requires further exploration.⁶

Conclusion

Melanoma incidence and disease burden is increasing, and the field of melanoma research is incredibly dynamic. Going forward, we believe dermatologists will continue to play a critical role both in primary disease prevention and detection as well as in detection of secondary treatment-related skin toxicities. ClinicalTrials.gov is an invaluable resource to keep interested parties informed, foster collaboration, identify potential barriers to success, and suggest future directions.